Vaccine Design and Testing – News and Features

Re-vaccination against SARS-CoV-2 promotes the development of broadly inhibitory antibodies against a wide range of variants, which supports the use of yearly booster vaccines.

They have discovered that a vaccine adjuvant – or “booster” – called C100 promotes potent anti-tumour immunity when it is injected directly into tumours in an animal model.

Pairing a personalized dendritic cell vaccine with an immune-boosting compound improves the immune response to malignant gliomas.

Many vaccines, including the Novavax COVID-19 vaccine, contain adjuvants that stimulate the immune system to mount a stronger defense. Producing one such adjuvant in yeast promises to make it less expensive and more widely available.

A major clinical trial has found that an additional COVID-19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against the virus.

A biomaterial vaccine enhances and sustains lymph node expansion following vaccination, boosting anti-tumor immunity in an animal model.

A new mRNA vaccine has shown promise in activating the immune system against a highly lethal type of brain tumor, according to results from a first-in-human clinical trial of four adult patients with glioblastoma.

In this interview, Professor Lawrence Young discusses the current interest in Epstein-Barr virus (EBV) vaccines for combatting multiple sclerosis and his thoughts on the future direction of EBV research.

Michelle C. Werner discusses how tRNAs could transform the drug development paradigm from gene-centric to gene-agnostic and accelerate new therapies for 30 million or more patients whose genetically driven disease can be classified under Stop Codon Disease.

A novel hydrogel therapy could be a first line of defense against viruses and other biological threats.